DK0413343T3 - Furanderivater - Google Patents

Furanderivater

Info

Publication number
DK0413343T3
DK0413343T3 DK90115731.3T DK90115731T DK0413343T3 DK 0413343 T3 DK0413343 T3 DK 0413343T3 DK 90115731 T DK90115731 T DK 90115731T DK 0413343 T3 DK0413343 T3 DK 0413343T3
Authority
DK
Denmark
Prior art keywords
furan derivatives
gastrointestinal
enterokinetic
expected
activity
Prior art date
Application number
DK90115731.3T
Other languages
Danish (da)
English (en)
Inventor
Setsuya Sasho
Shunji Ichikawa
Hiromasa Kato
Hiroyuki Obase
Katsuichi Shuto
Yoshimasa Oiji
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of DK0413343T3 publication Critical patent/DK0413343T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
DK90115731.3T 1989-08-17 1990-08-16 Furanderivater DK0413343T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21192089 1989-08-17

Publications (1)

Publication Number Publication Date
DK0413343T3 true DK0413343T3 (da) 1995-12-11

Family

ID=16613857

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90115731.3T DK0413343T3 (da) 1989-08-17 1990-08-16 Furanderivater

Country Status (10)

Country Link
US (1) US5075301A (ja)
EP (1) EP0413343B1 (ja)
JP (1) JPH0730064B2 (ja)
AT (1) ATE125805T1 (ja)
CA (1) CA2023311C (ja)
DE (1) DE69021294T2 (ja)
DK (1) DK0413343T3 (ja)
ES (1) ES2075098T3 (ja)
GR (1) GR3017870T3 (ja)
HK (1) HK1006459A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
WO1993023360A1 (fr) * 1992-05-12 1993-11-25 Zeria Pharmaceutical Co., Ltd. Nouveaux sels d'ammonium quaternaires et utilisation de ces sels comme medicament
CN1063442C (zh) * 1995-05-18 2001-03-21 泽里新药工业株式会社 氨基噻唑衍生物、含有它们的药物组合物及其用途
CN1072652C (zh) * 1996-10-24 2001-10-10 泽里新药工业株式会社 取代的苯甲酰氨基噻唑衍生物以及含有它们的药物
US6152966A (en) * 1998-05-13 2000-11-28 Novo Nordisk A/S Treatment of cork with a phenol oxidizing enzyme
EP1124794A1 (en) 1998-11-05 2001-08-22 Novo Nordisk A/S Substituted 3,3-diamino-2-propenenitriles, their preparation and use
US6362205B2 (en) 1998-11-05 2002-03-26 Novo Nordisk A/S Substituted 3,3-diamino-2-propenenitriles, their preparation and use
WO2005055715A2 (en) * 2003-12-04 2005-06-23 Fmc Corporation Insecticidal n-(heteroarylalkyl) alkanediamine derivatives
CN111303087B (zh) * 2020-04-07 2021-08-10 自然资源部第三海洋研究所 呋喃酮类化合物及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
FI832520L (fi) * 1982-07-12 1984-01-13 Bristol Myers Co Farmaceutiska foerfaranden och sammansaettningar
US4458077A (en) * 1982-11-22 1984-07-03 American Home Products Corporation Heterocyclic anti-ulcer agents
GB2209163B (en) * 1987-08-28 1991-04-24 Toyama Chemical Co Ltd Amine derivative and its salt, process for producing the same, and anti-ulcer agent containing the same

Also Published As

Publication number Publication date
DE69021294T2 (de) 1996-01-25
EP0413343B1 (en) 1995-08-02
ATE125805T1 (de) 1995-08-15
JPH0730064B2 (ja) 1995-04-05
CA2023311A1 (en) 1991-02-18
JPH03163074A (ja) 1991-07-15
ES2075098T3 (es) 1995-10-01
GR3017870T3 (en) 1996-01-31
EP0413343A3 (en) 1992-04-22
EP0413343A2 (en) 1991-02-20
CA2023311C (en) 1999-11-02
US5075301A (en) 1991-12-24
DE69021294D1 (de) 1995-09-07
HK1006459A1 (en) 1999-02-26

Similar Documents

Publication Publication Date Title
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU90219I2 (fr) Tolcapone et ses dérivés pharmaceutiquement acceptables (TASMAR)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
LV10442A (lv) Panemiens pirimidina atvasinajumu iegusanai
KR870700602A (ko) 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU90769I2 (fr) Capecitabine et ses d-riv-es pharmaceutiquement acceptables (xeloda)
DK351789D0 (da) Furanderivater
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
DK0413343T3 (da) Furanderivater
KR910700046A (ko) 포르피린의 생산 및 용도
FR2623806B1 (fr) Esters d'acides 3,6-dihydro-1,5(2h)-pyrimidinecarboxyliques a action therapeutique
LV10436A (lv) Azola atvasinajumi un to iegusanas starpprodukti
LV10074A (lv) Aizvietoti bicikloheptadiona atvasinajumi un to iegusanas panemiens un herbicidi
JPS5419959A (en) Novel daunobicine derivative * production thereof and use of same as drug
SE7902915L (sv) 4-oxo-4h-pyrido(1,2-a)pyrimidin-3-n-(1h-tetrazol-5-yl) karboxamidderivat och deras anvendning sasom inhibitorer av allergiska reaktioner
DK329189D0 (da) Glycerolderivat og dets farmakologiske anvendelse
DK283586A (da) Penemderivater
KR900700484A (ko) 1,4:3,6-디안히드로 헥시톨 잘산염의 아미노프로판올 유도체,그의 제법 및 약제로서의 그의 용도
KR920007626A (ko) 벤조[b]티오펜-2-카르복시이미드아미드 유도체의 사용방법
FR2345152A1 (fr) Nouveaux derives 4-substitues d'acides et d'esters pyrazolo-(1,5-a)quinoxaline-3-carboxyliques
BE851997A (fr) Ergosine et ses sels d'addition d'acides physiologiquement acceptables
FR2604176B1 (fr) Derives fonctionnels du 7-oxabicyclo(2.2.1)heptane a action therapeutique
DE69018903D1 (de) Verwendung von Prostansäurederivaten zur Herstellung von Arzneimitteln zur Verbesserung der Ausscheidung von Nichtprotein in die Därme.
IT8847797A0 (it) Derivati dell' 1.3 -diossalano e dell'1.3-diossano e loro impiegocome medicamenti